Viela Bio announced today that it has incorporated as an independent, inflammation – and autoimmunity focused biotechnology company after separating from MedImmune, the global biologics research and development arm of AstraZeneca.    Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.    Bing Yao, Ph.D., formerly senior vice president, head of MedImmune’s Respiratory, I...